Methylprednisolone Addition in IVF Treatment of Infertile Couples

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01220791
Recruitment Status : Unknown
Verified October 2010 by Universitair Ziekenhuis Brussel.
Recruitment status was:  Recruiting
First Posted : October 14, 2010
Last Update Posted : October 14, 2010
Information provided by:
Universitair Ziekenhuis Brussel

Brief Summary:
Hypothesis to be tested is whether follicular addition of Methylprednisolone can efficiently control late follicular progesterone rise during IVF treatment

Condition or disease Intervention/treatment Phase
In Vitro Fertilization Other: In vitro fertilization treatment for infertility Phase 4

Detailed Description:
The aim is to investigate any potential advantages of adding cortisone supplementation from the follicular phase onwards with regard to premature luteinization, oocyte quality, embryo quality and pregnancy outcome.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Methylprednisolone vs. Placebo to Control Late Follicular Progesterone Elevation in GnRH-Antagonist IVF Cycles
Study Start Date : January 2009
Estimated Primary Completion Date : December 2010
Estimated Study Completion Date : December 2011

Arm Intervention/treatment
Active Comparator: Follicular Medrol
In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
Other: In vitro fertilization treatment for infertility
IVF treatment
Other Names:
  • pregnancy
  • progesterone
Placebo Comparator: No medrol group
Patients will receive only Antagonist protocol for IVF as usual
Other: In vitro fertilization treatment for infertility
IVF treatment
Other Names:
  • pregnancy
  • progesterone

Primary Outcome Measures :
  1. Progesterone rise above on the day of HCG [ Time Frame: up to 14 days of follicular ovarian stimulation ]
    Incidence or high progesterone on the day of HCG triggering

Secondary Outcome Measures :
  1. Clinical pregnancy rate [ Time Frame: Follow pregnancy until delivery ]
    Success rate in IVF cycles

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 36 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • less than 36, more than 10 antral follicles, FSH<12

Exclusion Criteria:

  • endometriosis stage III&IV,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01220791

Contact: Evangelos Papanikolaou, MD 0030 2310 424284

Biogenesis Recruiting
Thessaloniki, Pylaia, Greece, 55536
Contact: Evangelos Papanikolaou, MD,PhD    0030 2310 989160   
Sponsors and Collaborators
Universitair Ziekenhuis Brussel
Study Chair: Basil Tarlatzis, Professor BioGenesis

Additional Information:
Responsible Party: Papanikolaou Evangelos, HRG Identifier: NCT01220791     History of Changes
Other Study ID Numbers: Medrol005
First Posted: October 14, 2010    Key Record Dates
Last Update Posted: October 14, 2010
Last Verified: October 2010

Keywords provided by Universitair Ziekenhuis Brussel:
late follicular phase
pregnancy rates

Additional relevant MeSH terms:
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Prednisolone acetate
Methylprednisolone acetate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Neuroprotective Agents
Protective Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents